Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades

被引：7

作者：

Eskola, Vesa ^{[1
]}

Pohjankoski, Heini ^{[2
]}

Kroeger, Liisa ^{[3
]}

Aalto, Kristiina ^{[4
]}

Latva, Katariina ^{[2
]}

Korppi, Matti ^{[1
,5
]}

机构：

[1] Tampere Univ Hosp, Dept Pediat, POB 2000, FIN-33521 Tampere, Finland

[2] Pajjat Hame Dist Cent Hosp, Dept Pediat, Lahti, Finland

[3] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland

[4] Helsinki Univ Hosp, Dept Pediat, Helsinki, Finland

[5] Univ Tampere, Pediat Res Ctr, Tampere, Finland

来源：

ACTA PAEDIATRICA | 2018年 / 107卷 / 04期

关键词：

Biologics; Children; Cryopyrin-associated periodic syndrome; Interleukin-1; Periodic fever; SUSTAINED RESPONSE; OPEN-LABEL; CANAKINUMAB; EFFICACY; SAFETY; MANAGEMENT; RILONACEPT; PHENOTYPE; ANAKINRA; LIFE;

D O I：

10.1111/apa.14217

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Cryopyrin-associated periodic syndrome (CAPS) is caused by a mutation in the NLRP3 gene encoding cryopyrin production. Overproduction of interleukin-1 (IL-1) leads to symptoms that are associated with elevated inflammatory markers, including periodic fever and a rash. We provide a clinical overview of CAPS in children, including three Finnish case studies. Conclusion: When CAPS has been diagnosed, an IL-1 blockade with biological should be introduced to lessen the symptoms and to prevent the progression of organ damage.

引用

页码：577 / 580

页数：4

共 50 条

[1] Anakinra for cryopyrin-associated periodic syndrome
Kone-Paut, Isabelle
Galeotti, Caroline
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (01) : 7 - 18
[2] Serum amyloid protein A concentration in cryopyrin-associated periodic syndrome patients treated with interleukin-1 beta antagonist
Pastore, S.
Paloni, G.
Caorsi, R.
Ronfani, L.
Taddio, A.
Lepore, L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) : S63 - S66
[3] Interleukin-1 beta inhibitors for the treatment of cryopyrin-associated periodic syndrome
Dhimolea, Eugen
APPLICATION OF CLINICAL GENETICS, 2011, 4 : 21 - 27
[4] Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome
Kuemmerle-Deschner, Jasmin B.
Hofer, Ferdinand
Endres, Theresa
Kortus-Goetze, Birgit
Blank, Norbert
Weissbarth-Riedel, Elisabeth
Schuetz, Catharina
Kallinich, Tilmann
Krause, Karoline
Rietschel, Christoph
Horneff, Gerd
Benseler, Susanne M.
RHEUMATOLOGY, 2016, 55 (04) : 689 - 696
[5] Cryopyrin-associated periodic syndrome
Kuemmerle-Deschner, B.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2012, 71 (03): : 199 - +
[6] Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome
Kone-Paut, Isabelle
Galeotti, Caroline
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (10) : 1083 - 1092
[7] Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes What did we learn?
Kone-Paut, Isabelle
Piram, Maryam
AUTOIMMUNITY REVIEWS, 2012, 12 (01) : 77 - 80
[8] Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome
Kilic, Huseyin
Sahin, Sezgin
Duman, Cisem
Adrovic, Amra
Barut, Kenan
Turanli, Eda Tahir
Yildirim, Senihe Rengin
Kizilkilic, Osman
Kasapcopur, Ozgur
Saltik, Sema
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2019, 23 (03) : 466 - 472
[9] Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
Quartier, Pierre
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2011, 3 : 9 - 18
[10] Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism
Church, Leigh D.
McDermott, Michael F.
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (01): : 14 - 15

← 1 2 3 4 5 →